1. Market Research
Customer Support

Talk to Ahmad

+1 718 618 4302

Top Countries

  • All
    • Australasia

Publication dates

Companies

  • All
    • Amgen Inc.

Publishers

2 reports for Lymphoma (page 1)

Purchase Reports From Reputable Market Research Publishers

Rheumatoid Arthritis: Global Drug Forecast and Market Analysis to 2027

  • $ 10995
  • January 2019
  • 201 pages

ALTHOUGH CELLTRION' S TRUXIMA WAS SIMILARLY TREATED BY THE FDA, THE COMPANY COMPLIED WITH REQUESTS FOR ADDITIONAL DATA AND IN NOVEMBER 2018, CELLTRION' S TRUXIMA WAS APPROVED, BUT ONLY FOR THE TREATMENT OF B-CELL NON-HODGKIN AND FOLLICULAR LYMPHOMAS (CELLTRION, PRESS RELEASE, ## NOV

  • Biosimilar
  • Lymphoma
  • Therapy
  • Australasia
  • Amgen Inc.

PharmaPoint: Rheumatoid Arthritis - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • February 2017
  • 403 pages

HOWEVER, PATIENTS WITH RA ARE KNOWN TO BE AT A HIGHER RISK FOR DEVELOPING LYMPHOMA.

  • Biosimilar
  • Epidemiology
  • Lymphoma
  • Australasia
  • Amgen Inc.


View report >

Cancer Statistics in Australia and Australasia

  • September 2011
  • 87 pages

TABLE ##. ##: ESTIMATED LEADING CAUSES OF THE CANCER BURDEN OF DISEASE DALYS LUNG PROSTATE BOWEL MELANOMA LYMPHOMA OTHER TOTAL ##, ## ##, ## ##, ## ##, ## ##, ## ##, ## ##, ## % OF CANCER BURDEN ## ## ## ## ## ## ## CANCER TYPE DALYS BREAST LUNG BOWEL OVARY PANCREAS OTHER TOTAL ##, ## ##, ##

  • Cancer
  • Hospital
  • Australasia
  • Australia
  • Amgen Inc.

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on